

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 September 2005 (29.09.2005)

PCT

(10) International Publication Number
WO 2005/090400 A1

(51) International Patent Classification⁷: C07K 14/52,
14/54, 14/715, A61K 38/00

(21) International Application Number:
PCT/GB2005/001037

(22) International Filing Date: 18 March 2005 (18.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0406135.4 18 March 2004 (18.03.2004) GB
0407760.8 5 April 2004 (05.04.2004) GB

(71) Applicant (for all designated States except US): THE
UNIVERSITY COURT OF THE UNIVERSITY OF
GLASGOW [GB/GB]; Gilbert Scott Building, University
Avenue, Glasgow G12 8QQ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LIEW, Foo, Yew
[GB/GB]; Division of Immunology, Infection and Inflam-
mation, University of Glasgow, Western Infirmary, Glas-
gow G11 6NT (GB). WEI, Xiao-Qing [GB/GB]; Division
of Immunology, Infection and Inflammation, University of
Glasgow, Western Infirmary, Glasgow G11 6NT (GB).

(74) Agents: FORREST, Graham et al.; Mewburn Ellis LLP,
York House, 23 Kingsway, London Greater London WC2B
6HP (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: IMMUNOSUPPRESSIVE CYTOKINE

(57) Abstract: The EBI3-p35 cytokine is shown for the first time to be capable of inhibiting immune responses mediated or controlled by T cells via an effect on suppressor T cells. This suggests that EBI3-p35 may be therapeutically effective in a variety of inflammatory and autoimmune conditions including arthritis, atherosclerosis, allograft rejection, and allergies such as asthma.

WO 2005/090400 A1